Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ken Kato
Institutions:
National Cancer Center Hospital,
National Cancer Center Hospital
Observed institutions:
National Cancer Center Hospital,
National Cancer Center Hospital
ORCID:
0000-0002-1733-5072
Observed ORCID:
0000-0002-1733-5072
OpenAlex ID:
A5147846959
Optimal Timing of Surgery Following Neoadjuvant Therapy for Surgical and Oncological Outcomes in Advanced Esophageal Squamous Cell Carcinoma: An Exploratory Analysis of JCOG1109
2026
·
Ryosuke Kita
, Ken Kato
, et al.
·
Annals of Surgical Oncology
·
3
PDF
First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in adults with advanced or metastatic esophageal squamous cell carcinoma: a Japanese subgroup analysis of RATIONALE-306 with ≥ 3 years of follow-up
2026
·
Takashi Ogata
, Takashi Kojima
, et al.
·
Esophagus
·
1
PDF
P1.084. Exploring the Role of Adjuvant Nivolumab After Neoadjuvant FLOT Followed by Surgery in Resectable ESCC: Implications for Cisplatin-Unfit Patients
2026
·
Ryuichi Morita
, Shun Yamamoto
, et al.
·
Diseases of the Esophagus
P1.088. Reduced-Dose Cisplatin-Based Preoperative Chemotherapy vs. Surgery Alone for Cisplatin-Unfit Esophageal Cancer: A Multicenter Retrospective Study in Japan
2026
·
Shota Fukuoka
, Taisuke Hosokai
, et al.
·
Diseases of the Esophagus
PDF
P1.116. Comparison Between Nivolumab + Ipilimumab, FOLFOX, and Nivolumab + FOLFOX Therapy as First-Line Therapy for Cisplatin-Unfit Advanced Esophageal Squamous Cell Carcinoma
2026
·
Nozomu Ogura
, Shun Yamamoto
, et al.
·
Diseases of the Esophagus
PD07.01. Prognostic Factors in Patients Receiving Neoadjuvant DCF Chemotherapy for Esophageal Squamous Cell Carcinoma: A Supplementary Analysis of JCOG1109
2026
·
Takako Yoshii
, Tomoya Yokota
, et al.
·
Diseases of the Esophagus
Inter-institutional heterogeneity in high-volume esophageal cancer centers: an ancillary study of JCOG1109 (JCOG2308A)
2026
·
Ryosuke Kita
, Ryunosuke Machida
, et al.
·
Esophagus
Efficacy and safety of definitive chemoradiotherapy for locoregional recurrence of esophageal squamous cell carcinoma following surgery, predominantly after neoadjuvant chemotherapy
2026
·
Kentaro Harada
, Shun Yamamoto
, et al.
·
Annals of Esophagus
First-line pembrolizumab plus chemotherapy versus chemotherapy alone for advanced esophageal cancer: 5-year extended follow-up in the Japanese subgroup of KEYNOTE-590
2026
·
Ken Kato
, Takashi Kojima
, et al.
·
Esophagus
PDF
Tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the Asian subgroup of the RATIONALE-305 study
2026
·
Ken Kato
, Rui-Hua Xu
, et al.
·
Current Medical Research and Opinion
PDF
Show more works
View as search
Works count:
10
Citation count:
4
H-index:
1
I10-index:
Year
Topic
Type